Vienna, Austria, 2017-09-22 - NBE-Therapeutics presented update on R&D activities at 2nd Annual Cancer Immunotherapy Summit
Roger R. Beerli, CSO of NBE-Therapeutics, invited to present an update on the company's ADC discovery activities
Roger R. Beerli has been invited for a presentation at the "2nd Annual Cancer Immunotherapy Summit" 2017. The conference is hosted by Von Lanthen group and is a premier event in the immunotherapy area (see: http://vonlanthengroup.com/en/events/2nd-annual-cancer-immunotherapy-summit.html). Roger's presentation took place on September 22, at 1:30 pm.
Recent news feed
RSS feed from: